Novartis’ Cosentyx approved in China for plaque psoriasis
April 2, 2019Manufacturing and Production, Sales and Marketing China, Cosentyx, Novartis, pharma, psoriasis
Novartis has revealed that its interleukin-17A (IL-17A) Cosentyx (secukinumab) has been authorised for use in China in the treatment of …
NICE recommends Eli Lilly’s Verzenio in combination with Fulvestrant for breast cancer
April 2, 2019Manufacturing and Production CDF, Cancer, NICE, breast cancer, britain, oncology
Britain’s cost effectiveness body, the National Institute for Health and Care Excellence (NICE), has recommended Eli Lilly’s Verzenio (abemaciclib) in …
Teva’s Ajovy injection secures EU approval for the prevention of migraine
April 2, 2019Manufacturing and Production, Sales and Marketing EU, Europe, Teva, ajovy, migraine, pharma
Teva has announced that its calcitonin gene-related peptide (CGRP) inhibitor Ajovy (fremanezumab) has been awarded marketing authorisation by the European …
China approves Keytruda for non-small cell lung cancer
April 2, 2019Manufacturing and Production China, MSD, Merck and Co, USA, keytruda, lung cancer, pharma
US firm MSD has won approval for Keytruda in China. The cancer immunotherapy has thus become the first PD-1 inhibitor …
Novartis must face kickback allegations in court
April 2, 2019Manufacturing and Production Novartis, US, government, kickbacks, prescriptions, whistle blower, whistle-blower
The US government has accused Novartis of paying doctors millions of dollars in kickbacks as part of a “company-wide kickback …
Artios Pharma name experienced oncologist as company’s new CMO
April 1, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Artios Pharma, CMO, Cancer, DDR, oncology
British biotech Artios Pharma have appointed experienced oncologist Dr Ian Smith, as the company’s new Chief Medical Officer (CMO). Dr …
How I learned to stop worrying and love the placebo effect
April 1, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing clinical trials, feature, pharma, placebo effect
Louis Goss talks to Harvard Medical School placebo expert Dr Ted Kaptchuk in asking what the placebo effect means for …
CHMP recommendation for bluebird bio’s gene therapy in β-thalassaemia
April 1, 2019Research and Development, Sales and Marketing Bluebird Bio, CHMP, EMA, Zynteglo, gene therapy, β-thalassaemia
Massachusetts-based bluebird bio has taken a significant leap forward in its pursuit of regulatory authorisation for its first gene therapy, …
Indian authorities say J&J’s baby shampoo contains ‘harmful ingredients’
April 1, 2019Sales and Marketing Cancer, India, J&J, JJ, Johnson & Johnson, Rajasthan, baby shampoo, formaldehyde
Indian authorities in the state of Rajasthan have said that samples taken from Johnson & Johnson’s baby shampoo contained ‘harmful …
Novartis inks $1.6 billion deal with immunology biotech IFM Therapeutics
April 1, 2019Sales and Marketing Atlas Venture, Boston, IFM Therapeutics, Novartis, pharma
Swiss firm Novartis has agreed to pay a sum of $310 million upfront to Boston inflammation specialist IFM Therapeutics, as …
Roche’s Tecentriq combo shows promise in first-line triple-negative breast cancer
April 1, 2019Research and Development, Sales and Marketing Cancer, Roche, breast cancer, pharma, tecentriq
Roche has revealed new Phase 1b data on a new Tecentriq combo, showing early promise in the first-line treatment of …
Lyrica to be made class C drug in Northern Ireland
April 1, 2019Sales and Marketing Lyrica, Northern Ireland, class c, illegal drugs, pain, pregabalin
Pregabalin – sold under the brand name Lyrica – will now be treated as a class C drug in Northern …
AstraZeneca and Daiichi Sankyo partner up for $6.9 billion cancer collaboration
March 29, 2019Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Cancer, Daiichi Sankyo, pharma
AstraZeneca and Daiichi Sankyo have announced a new collaboration agreement to the tune of potentially $6.9 billion which will see …
Top Ten most popular articles on Pharmafile.com this week!
March 29, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
A Japanese journalist was ordered to pay Â¥3.3 million to an anti-vaccine researcher, this week, after a court found her …
England’s antidepressant prescriptions double to 70m in a decade
March 29, 2019Medical Communications England, UK, antidepressants, anxiety, depression, pharma
Figures released by NHS Digital have revealed that prescriptions for antidepressants in the UK have risen to 70.9 million, almost …
ABPI calls for temporary export ban in effort to prevent shortages in case of no-deal Brexit
March 29, 2019Medical Communications ABPI, UK, brexit, drug shortages, export market
The Association of the British Pharmaceutical Industry (ABPI) has called for a temporary ban on exports as a means of …
Sacklers fraudulently transferred funds to dodge litigation, lawsuit says
March 29, 2019Medical Communications Litigation, New York, OxyContin, Purdue Pharma, Sackelr, opioids
New York state prosecutors have filed a lawsuit against members of the Sackler family, alleging the Purdue Pharma controllers fraudulently …
Vertex destroyed nearly 8,000 packs of Orkambi in 2018
March 28, 2019Medical Communications, Sales and Marketing Briatin, Orkambi, UK, Vertex, cystic fibrosis
Vertex destroyed nearly 8,000 packs of the $272,000 a year cystic fibrosis drug Orkambi in 2018, the company said in …
Working Life: Dr Paul-Peter Tak, ex-Senior Vice President, Development Lead and Chief Immunology Officer at GSK, Venture Partner at Flagship Pioneering
March 28, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing GSK, Working Life, feature
Dr Paul-Peter Tak, ex-Senior Vice President, Development Lead and Chief Immunology Officer at GSK, Venture Partner at Flagship Pioneering.How did …
J&J’s antihistamine-releasing contact lens shows promise in Phase 3 trials
March 28, 2019Research and Development J&J, JJ, eye care, pharma
Johnson and Johnson has unveiled new Phase 3 data on its antihistamine-releasing contact lens, showing that the investigational product led …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
